Tools
Register Login

biolyon.com

YOUAH Home » more biotech news » Radium-223 dichloride in prostate cancer Major added benefit for certain patients
Friday, 20 Oct 2017

Radium-223 dichloride in prostate cancer Major added benefit for certain patients

Radium-223 dichloride has been approved since November 2013 for men with advanced prostate cancer, in whom hormone blockade is no longer effective, and symptomatic bone metastases, but without visceral metastases. In an early benefit assessment, researchers examined whether this new drug offers an added benefit over the appropriate comparator therapy. No evaluable data were available for the comparison with docetaxel in patients in whom prolongation of life was the primary treatment goal. Hence an added benefit is not proven for this comparison.

Read more: Radium-223 dichloride in prostate cancer Major added benefit for certain patients

social

FacebookTwitterDiggDeliciousStumbleuponGoogle BookmarksRedditNewsvineTechnoratiLinkedinMixx